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We sought to determine the eﬀect of dipeptidyl peptidase IV (DPP-IV) inhibition on streptozotocin diabetes-induced vascular
and neural dysfunction. After 4 weeks of untreated diabetes, rats were treated for 12 weeks with Alogliptin (DPP-IV inhibitor).
Diabetes caused a slowing of motor and sensory nerve conduction velocity, thermal hypoalgesia, reduction in intraepidermal
nerve ﬁber density in the hindpaw, and impairment in vascular relaxation to acetylcholine and calcitonin gene-related peptide in
epineurial arterioles. Treatment signiﬁcantly improved motor nerve conduction velocity and thermal response latency. Sensory
nerve conduction velocity was marginally improved with treatment of diabetic rats, and treatment did not improve the decrease
in intraepidermal nerve ﬁber density. Vascular relaxation by epineurial arterioles to calcitonin gene-related peptide but not
acetylcholine was signiﬁcantly improved with treatment. These studies suggest that some but not all vascular and neural
complications associated with type 1 diabetes can be improved with the inhibition of DPP-IV activity.
1.Introduction
My laboratory has focused on the role of microvascular
dysfunction in the development and progression of diabetic
neuropathy. Studies in types 1 and 2 diabetic rats have
demonstrated that impaired vascular reactivity precedes the
development of nerve dysfunction [1, 2]. In this study,
we were interested in determining the potential beneﬁts of
treating type 1 diabetic rats with a dipeptidyl peptidase-IV
inhibitor on microvascular and neural complications.
Dipeptidyl peptidase-IV inhibitors alone or in combi-
nation with other therapies are being promoted for the
treatment of type 2 diabetes, but little is known about
potential beneﬁts of these inhibitors in type 1 diabetes [3].
In vivo dipeptidyl peptidase-IV degrades and inactivates
glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP). These incretin hormones
are released by gut endocrine cells and play an impor-
tant role in glucose homeostasis primarily by regulating
blood glucose levels through stimulating glucose-dependent
insulinsecretion,reducingglucagonsecretionandslowingof
gastric emptying [4, 5]. The degradation of these peptides by
dipeptidyl peptidase-IV is responsible for their short half life
in circulation [4, 6].
Dipeptidyl peptidase-IV or T-cell activation antigen
CD26 is a serine exopeptidase that cleaves X-proline dipep-
tides from the N-terminus of polypeptides [7]. The enzyme
is a type II transmembrane glycoprotein and is expressed
on the surface of many cell types including the kidney,
liver, and endothelial cells of blood vessels that drain the
intestinal mucosa and can be found in soluble form in the
circulation [6–9]. The inhibition of dipeptidyl peptidase-IV
has been shown to improve glycemic control in patients with
type 2 diabetes [8–10]. In rodent models of type 2 diabetes,
inhibition of dipeptidyl peptidase-IV leads to improvement
in glycemic control and is associated with an increase in
glucose-dependent insulin secretion and restoration of β
cell mass [10]. Dipeptidyl peptidase-IV inhibition of animal
models of type 2 diabetes has also been associated with
improving hyperlipidemia, inﬂammation, and hypertension
[11]. For treatment of type 2 diabetes dipeptidyl peptidase-
IV, inhibitors are becoming widely accepted because of2 Experimental Diabetes Research
their low risk of hypoglycemia; they are weight neutral,
a n da p p e a rt od e c r e a s eβ-cell apoptosis and increase β-cell
survival. However, little information is available whether
these inhibitors are eﬀective in treatment of complications
in animal models of type 1 diabetes [5]. In type 1 diabetes,
insulin secretion is impaired due to loss of β-cells. Thus,
any beneﬁcial eﬀects realized by dipeptidyl peptidase-IV
inhibitors would be due to mechanisms other than increased
insulin secretion. Using streptozotocin-treated diabetic rats,
we sought to determine whether the inhibition of dipeptidyl
peptidase-IV activity improves vascular or neural complica-
t i o n si nt y p e1d i a b e t e s .
2.MaterialsandMethods
Unless stated otherwise, all chemicals used in these studies
were obtained from Sigma Chemical Co. (St. Louis, MO).
2.1. Animals. Male Sprague-Dawley (Harlan Sprague Daw-
ley, Indianapolis, ind, USA) rats 12 weeks of age were
housed in a certiﬁed animal care facility, and food (Harlan
Teklad, #7001, Madison, wis, USA) and water were provided
ad libitum. All experiments were conducted in accordance
with international standards on animal welfare and were
compliant with all institutional and National Research
Council’s guidelines for use of animals (ACURF protocol
0210257). Diabetes was induced by intravenously injecting
streptozotocin (55mg/kg in 0.9%NaCl). Control rats were
injected with vehicle alone. Diabetes was veriﬁed 72h later
by evaluating blood glucose levels with the use of glucose-
oxidase reagent strips (Lifescan Inc., Milpitas, calif, USA).
Rats having blood glucose level of 300mg/dL (16.7mM) or
greater were considered to be diabetic.
Four weeks after the veriﬁcation of diabetes two groups
of diabetic, rats were established: an untreated group and
a group treated with Alogliptin ((dipeptidyl peptidase-IV
inhibitor) Takeda 200mg/kg in the diet). The supplemental
diet was prepared by mixing Alogliptin in the meal form
of the diet followed by the formation of pellets and drying
in a vacuum oven for 16h at 37◦C. The treatment phase of
the study lasted 12 weeks. Alogliptin is a novel, orally active,
quinazolinone-based, and noncovalent dipeptidyl peptidase-
IV inhibitor. In vitro studies have indicated that Alogliptin
exhibits more than 10,000 fold selectivity for dipeptidyl
peptidase-IV over the closely related serine proteases dipep-
tidyl peptidase VIII or IX. This high selectivity may be
important since the inhibition of dipeptidyl peptidase VIII
or IX has been reported to be associated with multiorgan
toxicity [4]. The pharmacokinetic, pharmacodynamic and
eﬃcacy proﬁles for Alogliptin has been reported in rats,
dogs, and monkeys [4]. The dosage of Alogliptin used in
this study was based on pharmacokinetic data [4]. Based
on the amount of food consumed, diabetic rats treated with
Alogliptin received about 10–20mg/kg rat per day. For this
study, all diabetic rats were treated with 2-3 units of Lantus
insulineveryotherdayinordertomaintainweight.Thisdose
of insulin did not correct hyperglycemia. Insulin treatment
was discontinued 3days prior to the terminal experiment.
Serum insulin values were determined and were found to
be very low or undetectable in both treated and untreated
diabetic rats (data not shown). A set of control rats were
also treated with Alogliptin, and results from these rats
demonstrated that Alogliptin had no eﬀect on neural or
vascular function of epineurial arterioles (data not shown).
2.2. Thermal Nociceptive Response. On the day before ter-
minal studies, thermal nociceptive response in the hindpaw
was measured using the Hargreaves method as previously
described [12].
2.3. Motor and Sensory Nerve Conduction Velocity and
Biological and Oxidative Stress Markers. On the day of
terminal studies, rats were weighed and anesthetized with
Nembutal i.p. (50mg/kg, i.p., Abbott Laboratories, North
Chicago, ill, USA). Nonfasting blood glucose was deter-
mined. Hemoglobin A1C levels were determined using a
Glyco-tek aﬃnity column kit (Helena Laboratories, Beau-
mont, tex, USA). Serum samples were collected for determi-
nation, of free fatty acid, triglyceride, and free cholesterol,
using commercial kits from Roche Diagnostics, Mannheim,
Germany; Sigma Chemical Co., St. Louis, mlo, USA; and
Bio Vision, Mountain View, calif, USA, respectively. Serum
thiobarbituric acid reactive substances (TBARS) levels were
determined as a marker of oxidative stress as previously
described [13]. Serum dipeptidyl peptidase-IV activity was
measured using a kit from eBioscience (Vienna, Austria).
This assay was performed to conﬁrm that Alogliptin
decreased dipeptidyl peptidase-IV activity in treated rats.
DatainTable2demonstratesthatdiabetescausedanincrease
in dipeptidyl peptidase-IV activity in serum, but this was
not signiﬁcant. Treating diabetic rats with Alogliptin caused
a signiﬁcant decrease in serum dipeptidyl peptidase-IV
activity.
Motor nerve conduction velocity (MNCV) was deter-
minedaspreviouslydescribedusinganoninvasiveprocedure
in the sciatic-posterior tibial conducting system [1]. Sensory
nerve conduction velocity (SNCV) was determined using the
digital nerve to the second toe as described by Obrosova et
al. [14]. The MNCV and SNCV were reported in meters per
second.
2.4. Intraepidermal Nerve Fiber Density in the Hindpaw.
Immunoreactive intraepidermal nerve ﬁber proﬁles were
visualized using confocal microscopy. Samples of skin of
the right hindpaw were ﬁxed, dehydrated, and embedded in
paraﬃn. Sections (7μm) were collected and immuno stained
with anti-PGP9.5 antibody (rabbit antihuman, AbD serotic,
Morpho Sys US Inc., Raleigh, nc, USA) overnight followed
by treatment with secondary antibody Alexa Fluor 546 goat
anti rabbit (Invitrogen, Eugene, ore, USA). Proﬁles were
counted by two individual investigators that were blinded to
the sample identity. All immunoreactive proﬁles within the
epidermis were counted and normalized to epidermal length
[15, 16].Experimental Diabetes Research 3
Table 1: Eﬀect of treatment of streptozotocin-diabetic rats with
alogliptinonchangeinbodyweight,bloodglucoseandhemoglobin
A1C.
Determination Control
(11)
Diabetic
(12)
Diabetic +
Alogliptin
(9)
Start weight (g) 359 ± 4 362 ± 4 358 ± 6
End weight (g) 524 ± 9 334 ± 14a 373 ± 30a
Blood glucose
(mg/dL) 110 ± 5 578 ± 13a 536 ± 23a
Hb A1C( % ) 5 . 3± 0.3 13.9 ± 0.4a 13.1 ± 1.4a
Data are presented as the mean ± SEM. aP < 0.05 compared to control.
Parentheses indicate the number of experimental animals.
2.5. Vascular Reactivity in Epineurial Arterioles. Videomi-
croscopy was used to investigate in vitro vasodilatory respon-
siveness of epineurial arterioles vascularizing the region of
the sciatic nerve as previously described [16–19]. Cumu-
lative concentration-response relationships were evaluated
for acetylcholine (10−8–10−4 M) and calcitonin gene, related
peptide (10−11–10−8 M) using vessels from each group of
rats. At the end of each dose response curve for acetylcholine
or calcitonin gene, related peptide, papaverine (10−5 M) was
added to determine maximal vasodilation.
2.6. Data Analysis. Results are presented as mean ± SEM.
Comparisons between the groups were conducted using
one-way ANOVA and Bonferroni after test (Prism software;
GraphPad, San Diego, calif, USA). Concentration response
curves for acetylcholine and calcitonin gene-related peptide
werecomparedusingatwo-wayrepeatedmeasureanalysisof
variance with autoregressive covariance structure using proc
mixed program of SAS [17, 18]. A P value of less than 0.05
was considered signiﬁcant.
3. Results
3.1. Eﬀect of Treatment of Streptozotocin-Diabetic Rats with
Alogliptin on Weight and Blood Glucose. Data in Table 1
demonstrate that untreated or diabetic rats treated with
Alogliptin had reduced weight gain and at the end of the
study period weighed signiﬁcantly less than control rats. All
diabetic rats were hyperglycemic at the end of the study
period as indicated by signiﬁcantly elevated blood glucose
and hemoglobin A1Cl e v e l s( T a b l e1).
3.2. Eﬀect of Treatment of Streptozotocin-Diabetic Rats with
AlogliptinonSerumLipidandTBARSLevelsandACEActivity.
Datain Table2demonstrate thatserum TBARS,a marker for
oxidative stress, was signiﬁcantly increased in diabetic rats.
Treating diabetic rats with Alogliptin lowered serum TBARS,
but the diﬀerence was not signiﬁcant compared to untreated
diabetic rats. Diabetes caused a signiﬁcant increase in serum
triglycerides, free fatty acids, and cholesterol levels. Treating
diabetic rats with Alogliptin did not signiﬁcantly reduce the
hyperlipidemia.
Table 2: Eﬀect of treatment of streptozotocin-diabetic rats with
alogliptin on serum thio barbituric acid reactive substances,
triglycerides, free fatty acids, cholesterol and dipeptidyl peptidase-
IV activity.
Determination Control
(11)
Diabetic
(12)
Diabetic +
Alogliptin
(9)
TBARS (μg/mL) 0.78 ± 0.07 1.07 ± 0.06a 0.93 ± 0.12
Triglycerides (mg/dL) 25 ± 3 206 ± 27a 225 ± 46a
Free fatty acids
(mmol/L) 0.11 ± 0.03 0.56 ± 0.07a 0.41 ± 0.11a
Cholesterol (mg/dL) 82 ± 13 223 ± 38a 175 ± 35a
Dipeptidyl
peptidase-IV
activity (ng/mL)
24.0 ± 3.0 35.4 ± 5.1 18.3 ± 3.4b
Data are presented as the mean ± SEM. aP < 0.05 compared to control; bP <
0.05 compared to diabetic. Parentheses indicate the number of experimental
animals.
3.3. Eﬀect of Treatment of Streptozotocin-Diabetic Rats with
AlogliptinonNerveConductionVelocity,ThermalNociception,
and Intraepidermal Nerve Fiber Density. Motor and sensory
nerve conduction velocity was signiﬁcantly decreased in
diabetic rats (Figure 1). Treating diabetic rats with Alogliptin
was more eﬀective in improving motor nerve conduction
velocity than sensory nerve conduction velocity. Data in
Figure 2 demonstrate that after 16 weeks of diabetes rats
are hypoalgesic and treating diabetic rats with Alogliptin
improved thermal nociception. After 16 weeks of untreated
diabetes, there was a decrease in intraepidermal nerve ﬁber
proﬁles in the hindpaw (Figure 2). Treating diabetic rats with
Alogliptin did not signiﬁcantly improve innervation of the
hindpaw.
3.4. Eﬀect of Treatment of Streptozotocin-Diabetic Rats with
Alogliptin on Vascular Relaxation by Epineurial Arterioles.
In these studies, treatment with Alogliptin did not prevent
impairmentofacetylcholine-mediatedvascularrelaxationby
epineurial arterioles from diabetic rats (Figure 3).
Figure 4 provides data on the eﬀect of diabetes and
treatmentwithAlogliptinonvascularrelaxationmediatedby
calcitonin gene-related peptide in epineurial arterioles. Cal-
citoningene-relatedpeptideisthemostpotentvasodilatorof
epineurial arterioles that we have identiﬁed, and the potency
is decreased by chronic diabetes [19]. Treatment of diabetic
rats with Alogliptin signiﬁcantly improved calcitonin gene-
related peptide-mediated vascular relaxation in epineurial
arterioles (Figure 4).
4. Discussion
We previously reported that the inhibition of neutral
endopeptidase was an eﬃcacious treatment for vascular and
neural complications in streptozotocin diabetic rats [20,
21]. We attributed the eﬃcacy of the inhibition of neutral
endopeptidase to the protection of vasoactive peptides
from degradation [20–22]. We have also previously shown4 Experimental Diabetes Research
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Figure 1: Eﬀect of treatment of streptozotocin-diabetic rats with
Alogliptin on motor and sensory nerve conduction velocity. At 12
weeks of age rats were made diabetic using streptozotocin and 4
weeks later were divided into 2 groups. One group was fed a normal
diet and the other group was fed a diet containing Alogliptin for 12
weeks. A nondiabetic control group was also included. Afterwards,
motor and sensory nerve conduction velocity was examined as
described. Data are presented as the mean ± SEM in m/sec. The
number of rats in each group was the same as shown in Table 1.
∗P<0.05, compared to rats fed the standard diet (control), +P<
0.05, compared to untreated diabetic rats.
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Figure 2: Eﬀect of treatment of streptozotocin-diabetic rats with
Alogliptin on thermal nociception and intraepidermal nerve ﬁber
density. Rats were treated as describe in Figure 1.T h e r m a l
nociception and intraepidermal nerve ﬁber density was examined
as described. Data are presented as the mean ± SEM for thermal
nociception in sec and intraepidermal nerve ﬁber proﬁles per mm.
T h en u m b e ro fra t si ne a c hgr o u pw a st h es a m ea ss h o wni nT a b l e1.
∗P<0.05, compared to rats fed the standard diet (control), +P<
0.05, compared to untreated diabetic rats.
that the inhibition of angiotensin converting enzyme was
beneﬁcial in treating vascular and neural dysfunction in
streptozotocindiabeticrats[18].Bothneutralendopeptidase
-and angiotensin- converting enzyme are proteases whose
expression is increased in diabetes [23].
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Figure 3: Eﬀect of treatment of streptozotocin-diabetic rats with
Alogliptin on vascular relaxation by acetylcholine in epineurial
arterioles.RatsweretreatedasdescribeinFigure1.Pressurizedarte-
rioles(40mmHgandrangingfrom60to100μmluminaldiameter)
were constricted with U46619 (30–50%), and incremental doses of
acetylcholine were added to the bathing solution while recording
steady state vessel diameter. Data are presented as the mean of %
relaxation ± SEM. For these studies, two vessels were collected from
each rat, studied, and the data combined. The number of rats in
each group was the same as shown in Table 1. ∗P<0.05, compared
to rats fed the standard diet (control).
Dipeptidyl peptidase is another protease whose activity
may impact on the progression of diabetic complications.
inhibition of dipeptidyl peptidase IV has been promoted
as a treatment for type 2 diabetes [24–27]. In ob/ob
mice, chronic dipeptidyl peptidase IV inhibition increased
GLP-1 levels and improved β-cell function and glycemic
control and decreased triglycerides [28, 29]. In the high fat
fed/streptozotocin ICR (imprinting control region) mouse, a
nongenetic model of type 2 diabetes, the inhibition of dipep-
tidyl peptidase IV improved glycemic control and increased
β-cell function [10]. In the streptozotocin-nicotinamide
diabetic mouse or rat, rodent models for type 2 diabetes,
dipeptidyl peptidase IV inhibition improved hemoglobin
A1C levels, glucose intolerance, and lipid proﬁles and
increased GLP-1 levels [30, 31]. In Zucker diabetic fatty rats,
a genetic rodent model for type 2 diabetes, the inhibition of
dipeptidyl peptidase IV corrected glycemic dysmetabolism,
hypertriglyceridemia, inﬂammation, and hypertension [11].
Thus, it is well documented that dipeptidyl peptidase IV
inhibition is an eﬀective treatment for type 2 diabetes
althoughlittleisknownabouttheeﬀectofchronicdipeptidyl
peptidase IV inhibitor treatment on animal models of type 1
diabetes.
As we have previously reported that streptozotocin-
induced type 1 diabetes was associated with decreased motor
and sensory nerve conduction velocity, hypoalgesia, decrease
in intraepidermal nerve ﬁber density and decreased vascularExperimental Diabetes Research 5
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Figure 4: Eﬀect of treatment of streptozotocin-diabetic rats with
Alogliptin on vascular relaxation by calcitonin gene-related peptide
in epineurial arterioles. Arterioles were derived from rats as
described in Figure 3. Incremental doses of calcitonin gene-related
peptide(CGRP)wereaddedtothebathingsolutionwhilerecording
steady state vessel diameter. Data are presented as the mean of %
relaxation ± SEM. The number of rats in each group was the same
a ss h o w ni nT a b l e1. ∗P<0.05, compared to rats fed the standard
diet (control), +P<0.05, compared to untreated diabetic rats.
relaxation in response to acetylcholine and calcitonin gene-
related peptide by epineurial arterioles [20, 21]. The present
studies demonstrated that treatment with Alogliptin for 12
weeks, following 4 weeks of untreated diabetes, improved
motor and to a lesser extent sensory nerve conduction
velocity and thermal hypoalgesia but not nerve ﬁber density.
Previously, we have shown that pretreating rats or mice
with 3-O-methylglucose (5.5mmol/kg body weight) imme-
diately prior to the injection of streptozotocin prevented
hyperglycemia and development of neural complications
[32, 33]. Thus, it is unlikely that the onset of diabetes-
related complications in streptozotocin-treated rodents is
due to streptozotocin toxicity. These rats also had very low
tonondetectableseruminsulinlevelsthatwerenotimproved
with Alogliptin (data not shown). Thus, the beneﬁcial eﬀects
of Alogliptin treatment were likely due to changes unrelated
to improved insulin release and action.
Chronic treatment of streptozotocin-diabetic rats with
Alogliptin improved vascular function in epineurial arte-
rioles in response to calcitonin gene-related peptide but
not to acetylcholine in epineurial arterioles. The inability
of Alogliptin treatment to improve acetylcholine-mediated
vascular relaxation is likely due to the lack of eﬀect by
Alogliptin to reduce oxidative stress. It has been shown that
dipeptidyl peptidase IV converts brain-derived natriuretic
peptide into its short form which lacks vasodilatory activity
[26]. It is possible that Alogliptin may prevent degradation
of natriuretic peptides and perhaps calcitonin gene-related
peptide thereby preserving their vasodilatory properties.
Dipeptidyl peptidase IV also degrades other peptides with
vascular function, and preserving their activity in diabetic
rats could also improve vascular function and reduce
ischemia. In this regard, we found that Alogliptin treatment
improved motor and to a lesser extent sensory nerve
conduction velocity and thermal nociception but did not
improveintraepidermalnerveﬁberdensity.Moreover,unlike
many rodent models of type 2 diabetes, treatment of type
1 diabetic rats with a dipeptidyl peptidase inhibitor did not
improve hyperlipidemia or glycemic control. We attribute
the improvement in motor nerve conduction velocity by
Alogliptin to improved vascular relaxation in response to
calcitonin gene-related peptide.
Our results indicate an apparent dissociation between
improvement in thermal hypoalgesia and intraepidermal
nerve ﬁber density. Even though, we and others have shown
that drug treatment of diabetic rodents can improve both
sensory perception and intraepidermal nerve ﬁber density,
the current studies using treatment with Alogliptin did not
support this ﬁnding [20, 21, 34–36]. A similar result was
obtained in streptozotocin-diabetic C57Bl6/J mice treated
with Baicalein [37]. Beiswenger et al. [38] in a study
using streptozotocin-diabetic C57Bl6/J mice reported that
thermal hypoalgesia developed before a measureable reduc-
tion of intraepidermal nerve ﬁber density. Pain perception
involves a complex signaling transduction pathway involving
neuropeptides such as calcitonin gene-related peptide and
substance P. In these studies, we have demonstrated that
treatment with Alogliptin protected vascular relaxation in
response in calcitonin gene-related peptide in epineurial
arterioles. It is possible that Alogliptin also protected the
bioactivity and signaling cascade mediated by calcitonin
gene-related peptide and perhaps substance P involved in
pain perception. The reduction of intraepidermal nerve
ﬁbers in these studies was about 30%. Thus, suﬃcient ﬁbers
may remain to initiate normal pain perception as long as the
signaling cascade is not compromised.
Ours is not the ﬁrst study to examine the eﬀect of
dipeptidylpeptidaseIVinhibitortreatmentoftype1diabetic
rats. Jin et al. [39] reported that dipeptidyl peptidase IV
inhibitor treatment of type 1 diabetic rats for 32 weeks
prevented peripheral nerve degeneration. They concluded
that preserving GLP-1 levels may be useful in peripheral
neuropathy.Alogliptintreatmentofdiabeticratsinourstudy
reduced dipeptidyl peptidase IV activity, but we did not
measure the activity of GLP-1. Like the studies by Jin et al.
[39], our studies also demonstrated that treatment of type 1
diabeticratswithadipeptidylpeptidaseIVinhibitorpartially
preserved neural function. Some of our results also defer, for
instance intraepidermal nerve ﬁber loss was not prevented
in our studies [39]. This could be due to some important
diﬀerences in the two study designs. Jin et al. initiated their
studies using much younger animals [39]. Pathophysiology
of diabetes complications may diﬀer depending on the age
of animals at the onset of diabetes. In both studies treatment
was initiated four weeks after the induction of diabetes, and
our dose of inhibitor and the high dose used by Jin et al. were
similar although the duration of treatments was diﬀerent.
Our treatment period lasted 12 weeks, whereas the treatment6 Experimental Diabetes Research
period in the study by Jin et al. was 32 weeks [39]. It could
be that a longer treatment period would provide more time
for nerve regeneration. The drug used and delivery were also
diﬀerent in the two studies. In our study, Alogliptin was
delivered in the diet, and in Jin et al. vildagliptin was given
once daily in water [39]. These diﬀerences may account for
why we did not observe the protection of intraepidermal
nerve ﬁber density in our studies.
5. Conclusions
Studies were performed of the eﬀect of treating strepto-
zotocin type 1 diabetic rats with Alogliptin, a dipeptidyl
peptidase IV inhibitor, on vascular and nerve dysfunction.
We found that treatment with Alogliptin improved some
neural and vascular complications. It is becoming clear that
dipeptidyl peptidase IV inhibitors have multiple aﬀects and
may improve outcome by mechanisms unrelated to the
preservation of GLP-1 or GIP [40].
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